CHEK Profile
Check-Cap Ltd., a clinical-stage medical diagnostics firm, specializes in the development of a pioneering capsule-based technology for colorectal cancer screening. The company's flagship product, the C-Scan system, is designed to detect precancerous polyps and other structural abnormalities in the colon using ultra-low-dose X-ray imaging. This non-invasive screening method aims to enhance early detection and improve patient outcomes by providing a safer alternative to traditional colonoscopy.
The C-Scan system comprises three key components: the C-Scan Cap, an X-ray scanning capsule that is ingested by the patient to capture detailed images of the colon's inner lining; the C-Scan Track, a disposable system that attaches to the patient's back with biocompatible adhesive patches to monitor capsule movement; and the C-Scan View software, which processes and analyzes the data collected from the C-Scan Track. This software enables healthcare providers to review images, generate reports, and make informed decisions based on comprehensive diagnostic information.
Founded in 2004 and headquartered in Isfiya, Israel, Check-Cap Ltd. is at the forefront of innovative colorectal cancer screening technologies. The company's mission is to revolutionize the way colorectal cancer is detected by offering a less invasive, more patient-friendly option compared to traditional methods. Check-Cap's technology is designed to address the limitations of current screening practices and provide a critical tool for early cancer detection.
With a focus on advancing medical diagnostics and improving patient care, Check-Cap Ltd. continues to drive research and development efforts to refine its technology and expand its market presence. The company's commitment to innovation in colorectal cancer screening reflects its broader goal of enhancing healthcare outcomes and contributing to the fight against cancer.
|
